SCHEMBL3226629

SCHEMBL3226629

CN1CCN(c2cccc(Cl)c2)c2ccc(C#N)cc2C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 5/20 0.46
DRD3 P35462 4/20 0.46
KCNH2 Q12809 4/20 0.46
HSD17B3 P37058 2/20 0.41
FNTA P49354 5/20 0.41
FNTB P49356 5/20 0.41
NRAS P01111 1/20 0.41
HRAS P01112 1/20 0.41
PGGT1B P53609 1/20 0.41
BRD4 O60885 1/20 0.40
BRD2 P25440 1/20 0.40
DRD4 P21917 1/20 0.40
HTR2A P28223 1/20 0.40
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 1/20 0.39
HPGD P15428 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
TSHR P16473 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3233292 0.86 BRD4 (0.49) DRD2DRD3HSD17B3BRD4BRD2
SCHEMBL3234981 0.86 HRH4 (0.41) DRD2DRD3KCNH2DRD4ALDH1A1
SCHEMBL3225745 0.86 DRD2 (0.39) DRD2DRD3KCNH2ALDH1A1NSD2
SCHEMBL3226442 0.84 SLC6A2 (0.45) DRD2DRD3KCNH2BRD4BRD2
SCHEMBL3230403 0.82 ALDH1A1 (0.39) DRD2DRD3KCNH2BRD4BRD2
SCHEMBL3225923 0.81 DRD2 (0.48) DRD2DRD3KCNH2FNTAPGGT1B
SCHEMBL3232299 0.81 HTR3A (0.48) DRD2DRD3KCNH2MAPTHRH4
SCHEMBL3232660 0.81 DRD2 (0.52) DRD2DRD3KCNH2DRD4HTR2A
SCHEMBL3235711 0.81 HRH4 (0.41) DRD2DRD3DRD4HTR2AALDH1A1
SCHEMBL3226397 0.80 DRD2 (0.46) DRD2DRD3KCNH2DRD4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096546-B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-08-04 US disclosed
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2010-06-03 US disclosed
EP-2146722-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR Technology, Inc. (US) 2010-01-27 EP disclosed
WO-2008141081-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR TECHNOLOGY, INC. (US) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ADRA1B, ADRB1, ADRA1D DRD2 5/4885DRD3 12/4885KCNH2 537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.